Despite Advantages, Disparities in Access to Palliative Care in Kidney Cancer Remain
June 19th 2019Although palliative care has been shown to improve survival rates among patients with metastatic renal cell carcinoma, its utilization remains low while certain barriers and disparities still exist.
Read More
'Out of the Blue' Diagnosis Linked to a Family History of Cancer Now Empowers Others
June 12th 2019Sue Friedman, founder and executive director of FORCE, discussed how a breast cancer diagnosis at age 33 and a family history of cancer led to the creation of Facing Our Risk of Cancer Empowered.
Read More
Founding 'Faery' Shares Resources and Inspiration Behind Blue Faery Liver Cancer Association
June 11th 2019Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.
Read More
Venclexta Plus Gazyva Reduces Disease Progression by 65% in Patients with CLL
June 6th 2019The addition of Venclexta to Gazyva induced prolonged progression-free survival – or the time from treatment to disease worsening – among patients with previously untreated chronic lymphocytic leukemia.
Read More
New Targeted Antibody Shows Promise for Advanced Urothelial Cancer
June 3rd 2019After progressing on prior therapy, 44% of patients with locally advanced or metastatic urothelial cancer who were treated with enfortumab vedotin demonstrated a response to treatment, according to phase 2 study findings.
Read More
Kisqali Plus Endocrine Therapy Improves Survival in Breast Cancer Subgroup
June 3rd 2019The addition of Kisqali to standard-of-care endocrine therapy significantly improved overall survival for premenopausal women with advanced HR-positive/HER2-negative breast cancer compared with endocrine therapy alone.
Read More
Specialized Care Is Needed for Adolescent and Young Adult Cancer Survivors
June 11th 2018The survey contained questions on a range of issues they may have experienced, including pain, fatigue, as well as issues with sexual function, body image and finances. Researchers then looked at the anxiety and depression associated with those issues, and talked with patients about what they thought might be causing those problems.
Read More
Investigational Drug Shows Promise in Patients with Metastatic Urothelial Cancer
June 5th 2018Enfortumab vedotin may be a potential novel therapy for patients with locally advanced or metastatic urothelial cancer, according to updated phase 1 study findings presented during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
Read More
Broader Genetic Testing Can Save Costs, Determine Treatment Plans in Lung Cancer
June 1st 2018Using next-generation sequencing (NGS) to test patients with non-small cell lung cancer (NSCLC) for all known genetic mutations associated with the disease appeared to be faster and more cost-effective than testing for one gene at a time – not to mention the results could have treatment implications.
Read More
Genetic Counseling With Telemedicine Helps Patients in Community Practices
June 1st 2018Patients who would otherwise not have access to genetic counseling at community-based medical centers can benefit from the use of remote phone or video technology to take advantage of these services, according to study results presented at the American Society of Clinical Oncology Annual Meeting in Chicago on June 1-4.
Read More
Extending Progression-Free Survival in BRCA-Positive Breast Cancer
June 9th 2017“This is the first phase 3 study to show an advantage of a PARP inhibitor over standard of care chemotherapy in breast cancer patients with a BRCA mutation,” said principal OLYMPIAD investigator Mark E. Robson, M.D., Clinic Director of the Clinical Genetics Service at Memorial Sloan Kettering Cancer Center.
Read More
Drug Combination Is Effective in Urothelial Carcinoma
June 6th 2017When combined with the IDO1 inhibitor epacadostat, Keytruda (pembrolizumab), a PD-1 inhibitor, resulted in an overall response rate (ORR) of 35 percent in patients with advanced urothelial carcinoma, according to results from the phase 1/2 ECHO-202/KEYNOTE-037 trial.
Read More